PTIP inhibits proliferation, migration, and angiogenesis of retinal microvascular endothelial cells in a high-glucose environment
Jinfeng Zhang, Xiaohan Zhang, Changhua Gao, Cuiting Huang, Xuesong Lin

TL;DR
This study shows that PTIP reduces harmful cell growth and inflammation in retinal cells exposed to high glucose, which is relevant to diabetic retinopathy.
Contribution
The study reveals PTIP as a novel regulator of retinal cell behavior under high-glucose conditions, offering potential therapeutic insights for diabetic retinopathy.
Findings
PTIP overexpression suppressed RMEC proliferation, migration, and tube formation in high-glucose environments.
PTIP reduced inflammatory markers like IL-6, TNF-α, and oxidative stress in high-glucose-treated RMECs.
PTIP knockdown increased VEGF, MDA, and other pro-angiogenic and inflammatory factors in RMECs.
Abstract
The abnormal proliferation, migration, and angiogenesis of retinal microvascular endothelial cells (RMECs) are key pathological mechanisms involved in diabetic retinopathy (DR). This study aims to investigate the regulatory role of PAX interacting protein 1 (PTIP) in modulating proliferation, angiogenesis, and inflammatory responses in RMECs under high-glucose conditions. The levels of PTIP, VEGF, MDA, and SOD were measured in RMECs cultured under both normal and high-glucose conditions. A PTIP overexpression vector and a PTIP interference vector were constructed and transfected into RMECs exposed to high glucose. Cell proliferation was assessed using the CCK-8 assay, cell migration capacity was evaluated through wound healing assays, and tube formation ability was analyzed using Matrigel-based assays. Intracellular MDA and SOD levels were determined biochemically, while TNF-α and IL-6…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7- —http://dx.doi.org/10.13039/501100003392Natural Science Foundation of Fujian Province
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinal Diseases and Treatments · Ocular Diseases and Behçet’s Syndrome · Retinal and Macular Surgery
Introduction
Diabetic retinopathy (DR) is one of the leading causes of blindness worldwide, characterized primarily by retinal microvascular lesions (Ntentakis et al. 2024; Sinclair and Schwartz 2024). Chronic hyperglycemia induces endothelial cell damage via intricate pathophysiological mechanisms, resulting in significant retinal ischemia and hypoxia. This pathological state triggers the upregulation of multiple angiogenic factors, promoting the proliferation and migration of vascular endothelial cells (Bohler et al. 2024; Mishra et al. 2024). Subsequent sprouting leads to the formation of abnormal new blood vessels (Nouri et al. 2024). If left untreated, neovascularization can cause severe complications, including neovascular glaucoma, vitreous hemorrhage, and tractional retinal detachment, ultimately leading to profound vision loss (Li et al. 2024; Reddy et al. 2024). Therefore, identifying novel target molecules and developing more efficacious drugs to inhibit pathological neovascularization are of critical importance for delaying the progression of DR.
PAX interacting protein 1 (PTIP) is a protein that interacts with Pax2 and was initially identified via the yeast two-hybrid system in 2000 (Lechner et al. 2000). PTIP is a chromatin regulatory factor containing six BRCT domains, which is broadly expressed in the cell nucleus and is intricately involved in gene regulation, DNA replication, and DNA repair processes (Liang et al. 2024a, b; Tan and Xu 2024). Research has demonstrated that PTIP plays a critical role in regulating the onset and progression of various diseases, including diabetic nephropathy (Cao et al. 2021a, b), lung cancer (Wu et al. 2018), and acute myeloid leukemia (Das et al. 2018). However, to date, no research has explicitly reported the specific role of PTIP in the occurrence and progression of DR. Interestingly, Mu et al. demonstrated that PTIP is indispensable for vascular development in mouse embryos, and the point mutation (L5Jcs36) of PTIP can impair embryonic development in mice (Mu et al. 2008). Retinal microvascular lesions are the main pathological feature of DR (Chen et al. 2023). Therefore, this study aimed to investigate the effects of PTIP on the proliferation, migration, and angiogenesis of rat retinal microvascular endothelial cells (RMECs) in a high-glucose environment and investigated its underlying molecular mechanisms.
Materials and methods
Materials
RMECs (RAT-iCell-m009) and iCell Primary Endothelial Cell Culture System were purchased from iCell Bioscience Inc. (Shanghai, China). Cell counting kit-8 was purchased from Solaibao Technology Co., LTD (Beijing, China). Antibodies against PTIP, EGR3, VEGF, MMP3, MMP9, and β-actin were purchased from Abcam (Cambridge, UK). Malondialdehyde (MDA) assay kit and Superoxide Dismutase (SOD) assay kit were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Rat TNF-α ELISA Kit and Rat IL-6 ELISA Kit were purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd. (Shanghai, China). PTIP-pcDNA3.1 (+), si-PTIP-1, si-PTIP-2, si-PTIP-3, and si-NC were obtained from GENERAL BIOL (Chuzhou, China). The sequences of siRNAs targeting rat PTIP mRNA were si-PTIP-1: 5′ -GGUUAUUCAGCUUCUUAAATT UUUAAGAAGCUGAAUAACCTT-3′, si-PTIP-2: 5′ -GCUCCAGUUUCCACAGCAATT UUGCUGUGGAAACUGGAGCTT-3′, si-PTIP-3: 5′-GAAGGUGACUGCAGAGCUATT UAGCUCUGCAGUCACCUUCTT-3′, and si-NC: UUCUCCGAACGUGUCACGUTTACGUGACACGUUCGGAGAATT.
Cell culture and transfection
RMECs was cultured in iCell Primary Endothelial Cell Culture System at 37 °C in an atmosphere containing 5% CO_2_. PCR was used to detect whether RMECs were contaminated by mycoplasma on February 13, 2025, at iCell Bioscience Inc. We ensure that the cells used in the experiment are not contaminated with mycoplasma. Then, the in vitro DR model was constructed by treating RMECs with 40 mM glucose for 48 h. And cell transfection was performed using Lipofectamine 3000 reagent. After transfection for 48 hours, the following experiments were performed.
Quantitative real-time PCR (qRT-PCR)
Samples were collected and the total RNA was isolated using a Total RNA Miniprep Kit. Subsequently, cDNA synthesis was carried out following the instructions provided by the manufacturer. A qRT-PCR analysis was conducted using real-time PCR machine (CFX Connect™, Bio-Rad, Hercules, CA) under the following conditions: initial denaturation at 95 °C for 5 min, followed by denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s, extension from 65 to 95 °C with a temperature increment of 0.5°C every 5 s, 40 cycles. After completion of the reaction, average cycle threshold (Ct) values were determined for each gene as well as for the reference gene. The relative expression levels of genes were evaluated using the widely accepted method known as 2^−ΔΔCT^. The sequences of the primers are shown in Table 1.
Table 1.Primer sequenceGene symbolForward primerReverse primerPTIPGCTTCAAGCGGAGATCCTACCCACTGGCTCATCATCAAAGTCAAAGAPDHGACAACTTTGGCATCGTGGAATGCAGGGATGATGTTCTGG
Western blotting
The total protein was extracted and the content was tested using a BCA protein assay kit. Then, the protein (30 mg) was separated by 10% SDS-PAGE and transferred onto a PVDF membrane. Membranes for target protein (and β-actin) were blocked with 5% skimmed milk at 25 °C for 1 h. Relative membranes were incubated with primary antibody of PTIP (1:500), EGR3 (1:1000), VEGF (1:1000), MMP3 (1:1000), and MMP9 (1:1000), followed by incubation with secondary antibody for 1 h. Finally, the protein bands were tested by an ECL-detecting kit, and β-actin was served as loading control.
Measurement of MDA and SOD
The MDA and SOD content assays in the RMECs of different groups were performed according to the manufacturer’s protocol.
CCK-8 assay
Cell viability was measured using a cell counting kit-8. Briefly, cells (2 × 10^4^/well) were seeded in 96-well plate and cultured for 48 h. Then, each well was supplement with 10 µL CCK-8 solution and incubated for 1 h. Afterwards, the absorbance was measured using a microplate reader (SuPerMax3100, Shanghai Shanspu Biotechnology Co., Ltd., Shanghai, China) at the wavelength of 450 nm.
Wound healing assay
Scratch treatment was performed in each well using a 200-µL pipette tip. The wells were washed three times with PBS after discarding the culture medium, and scratches were photographed in incomplete culture medium. Cells were incubated, and scratch images were taken again after 24 h. Scratch areas at 0 and 24 h were calculated based on the images, and the wound healing rate of RMECs was determined.
Tube formation assay
RMECs from different treatment groups were harvested, followed by trypsinization, quantification, and seeding into 48-well plates pre-coated with matrix gel at a density of 40,000 cells per well. After 6 h of incubation, the cultures were examined and imaged, followed by data analysis.
Enzyme-linked immunosorbent assay (ELISA)
The TNF-α and IL-6 content assays in the supernatants of RMECs were performed according to the manufacturer’s protocol.
Immunofluorescence
RMECs were harvested after various treatments, fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.5% Triton X-100 for 20 min, and blocked with 5% BSA at 37 °C for 30 min. The samples were subsequently incubated overnight at 4 °C with an antibody. Following washing steps, the fluorescent secondary antibody Cy3 Goat Anti-Rabbit IgG (H + L) was applied. After restaining with DAPI, the slides were mounted and imaged under a fluorescence microscope (CKX53, Olympus).
Statistical analyses
SPSS 26.0 was applied for statistical analysis, and experimental data were expressed as mean ± standard deviation (x ± s). One-way ANOVA is used to compare the means of three or more independent groups, while paired samples t-tests are employed to assess the difference between two related groups, and P < 0.05 was considered a statistically significant difference.
Results
PTIP was down-regulated in RMECs treated with high glucose
Immunofluorescence and flow cytometry were used to identify the marker proteins (CD31) of RMECs (Fig. 1A, B); the results showed that CD31 were expressed positively in RMECs. As shown in Fig. 1C, CCK-8 was employed to explore the concentration of the in vitro DR model of RMECs induced by high glucose. The cell proliferation activity of RMECs in the 40 mM glucose treatment group was significantly higher than that in the 0 mM glucose treatment group (0 mM means there is no added glucose concentration), as evidenced by a marked difference between the two groups. To further confirm that this high-glucose concentration can effectively simulate the in vitro DR model, we measured the levels of MDA (Fig. 1D), SOD (Fig. 1E), and VEGF (Fig. 1F, G) in RMECs across different treatment groups. Compared with the 0 mM glucose treatment, the activity of SOD in RMECs of the 40 mM glucose treatment group was significantly reduced, whereas the levels of MDA content was markedly increased. Compared with the control group, the level of VEGF protein expression was markedly increased. Therefore, exposing RMECs to a 40 mM glucose concentration effectively establishes an in vitro model of DR. In addition, we found that the expression of PTIP protein was significantly decreased in the model group of RMECs (Fig. 1H). And this result suggests that PTIP can be involved in regulating the development of DR Models in vitro.Figure 1.PTIP was down-regulated in RMECs treated with high glucose. (A) The RMECs marker protein (CD31) was identified by immunofluorescence and (B) flow cytometry; (C) CCK-8 was employed to explore the concentration of the in vitro DR model of RMECs induced by high glucose; (D) SOD activity and (E) MDA concentration in RMECs of different groups were detected; (F) the protein expressions of VEGF and PTIP in different RMECs were detected by WB, (G**, **H) quantitative analysis of protein expression in different RMECs, (G) VEGF and (H) PTIP. Data are presented as the mean ± SD. *P < 0.05 vs. 0 mM or control.
Effect of PTIP overexpression on cell proliferation, migration, and inflammation factors of RMECs treated with high glucose
As shown in Fig. 2A–C, the transfection efficiency of PTIP overexpression vector in RMECs was verified by qRT-PCR (Fig. 2A) and WB (Fig. 2B, C). Compared with the OE-NC group, the mRNA and protein expressions of PTIP in OE-PTIP group were significantly increased in RMECs (P < 0.05). And this result confirms the successful overexpression of PTIP through transfection. Then, we used CCK-8 to detect the effect of PTIP overexpression on the proliferation activity of RMECs (Fig. 2D). Compared with the model + OE-NC group, the cell proliferation activity of RMECs in the Model + OE-PTIP group was significantly decreased. In addition, we further detected the migration ability of different RMECs by wound healing assay (Fig. 2E, F). Compared with the control group, the model group showed significantly increased cell migration ability. Compared with the model + OE-NC group, the model + OE-PTIP group exhibited significantly reduced cell migration ability. Besides, as shown in Fig. 2G–J, we employed distinct kits to quantify the levels of SOD, MDA, TNF-α, and IL-6 in RMECs across various treatment groups. Compared with the model + OE-NC group, the SOD activity of RMECs was significantly increased in the model + OE-PTIP group (P < 0.05), while the MDA, TNF-α, and IL-6 concentrations were significantly decreased (P < 0.05).Figure 2.Effect of PTIP overexpression on cell proliferation, migration, and inflammation factors of RMECs treated with high glucose. (A) Transfection efficiency of PTIP overexpression vector in RMECs was verified by qRT-PCR and (B, C) WB; (D) CCK-8 was used to detect the effect of PTIP overexpression on the proliferation of RMECs treated with high glucose; (E**, **F) the migration of different RMECs was detected by wound healing assay; (G) SOD activity, (H) MDA, (I) TNF-α, and (J) IL-6 concentration in RMECs of different groups were detected. Data are presented as the mean ± SD. *P < 0.05 vs. control; ^#^P < 0.05 vs. model + OE-NC.
Effect of PTIP overexpression on angiogenesis of RMECs treated with high glucose
To further analyze the tube formation ability in different RMECs, we used tube formation assay to analyze it (Fig. 3A). And the analysis results are shown in Fig. 3B and C. Compared with the control group, both Nb junctions and Tot. length in RMECs of the model group were significantly increased. However, compared with the model + OE-NC group, both Nb junctions and Tot. length in RMECs of the model + OE-PTIP group were significantly decreased. In addition, we further detected the expression of angiogenesis-related proteins (MMP9, MMP3, EGR3, and VEGF) and PTIP in different RMECs by WB (Fig. 3D–I). Compared with the control group, the protein expression of MMP9, MMP3, EGR3, and VEGF in the model group was significantly increased (P < 0.05), while the protein expression of PTIP in the model group was significantly decreased (P < 0.05). Besides, compared with the model + OE-NC group, the protein expression of MMP9, MMP3, EGR3, and VEGF in the model + OE-PTIP group was significantly decreased (P < 0.05), while the protein expression of PTIP in the Model + OE-PTIP group was significantly increased (P < 0.05). Interestingly, as shown in Fig. 4A–E, the expression of angiogenic-related proteins (MMP9, MMP3, EGR3, and VEGF) in RMECs of different groups was detected by immunofluorescence, and the results were consistent with that of WB. The above results indicate that PTIP overexpression can inhibit angiogenesis of RMECs treated with high glucose.Figure 3.Effect of PTIP overexpression on angiogenesis of RMECs treated with high glucose. (A) The tube formation ability of different RMECs was detected; (B**, **C) quantitative analysis of tube formation ability in different RMECs; (D) the protein expressions of MMP9, MMP3, EGR3, VEGF, and PTIP in different RMECs were detected by WB; (E-I) quantitative analysis of protein expression in different RMECs, (E) MMP9, (F) MMP3, (G) EGR3, (H) VEGF, and (I) PTIP. Data are presented as the mean ± SD. *P < 0.05 vs. control; ^#^P < 0.05 vs. model + OE-NC.Figure 4.Effect of PTIP overexpression on the protein expressions of VEGF, EGR3, MMP3, and MMP9 of RMECs treated with high glucose. (A) Immunofluorescence results of different RMECs. (B–E) Quantitative analysis of protein expression in different RMECs, (B) VEGF, (C) EGR3, (D) MMP3, and (E) MMP9.
Effect of interfering PTIP on cell proliferation, migration, and inflammation factors of RMECs treated with high glucose
As shown in Fig. 5A–C, si-NC and three different si-PTIP were transfected into RMECs, and the silencing effect of PTIP was verified by qPCR (Fig. 5A) and WB (Fig. 5B, C). Compared with the si-NC group, the PTIP mRNA expressions of RMECs in the si-PTIP-1 group were significantly decreased (P < 0.05), while the PTIP protein expressions of RMECs in the si-PTIP-1 and the si-PTIP-2 group were significantly decreased (P < 0.05). According to the results of silencing PTIP, we used si-PTIP-1 for follow-up experiments. Then, we used CCK-8 to detect the effect of silencing PTIP on the proliferation activity of RMECs (Fig. 5D). Compared with the model + si-NC group, the cell proliferation activity of RMECs in the model + si-PTIP group was significantly increased. In addition, we further detected the migration ability of different RMECs by wound healing assay (Fig. 5E, F). Compared with the model + si-NC group, the model + si-PTIP group exhibited significantly enhanced cell migration ability. Besides, as shown in Fig. 5G–J, we employed distinct kits to quantify the levels of SOD, MDA, TNF-α, and IL-6 in RMECs across various treatment groups. Compared with the model + si-NC group, the SOD activity of RMECs was significantly decreased in the model + si-PTIP group (P < 0.05), while the MDA, TNF-α, and IL-6 concentrations were significantly increased (P < 0.05).Figure 5.Effect of interfering PTIP on cell proliferation, migration, and inflammation factors of RMECs treated with high glucose. (A) Transfection efficiency of different si-PTIP in RMECs was verified by qRT-PCR and (B–C) WB; (D) CCK-8 was used to detect the effect of interfering PTIP on the proliferation of RMECs treated with high glucose; (E, F) the migration of different RMECs was detected by wound healing assay; (G) SOD activity, (H) MDA, (I) TNF-α, and (J) IL-6 concentration in RMECs of different groups were detected. Data are presented as the mean ± SD. *P < 0.05 vs. control; ^#^P < 0.05 vs. model + si-NC.
Effect of interfering PTIP on angiogenesis of RMECs treated with high glucose
Subsequently, tube formation assay was used to detect the tube formation ability of different treated RMECs (Fig. 6A–C). Compared with the model + si-NC group, both Nb junctions and Tot. length in RMECs of the model + si-PTIP group were significantly increased (P < 0.05). In addition, we detected the expression of angiogenesis-related proteins (MMP9, MMP3, EGR3, and VEGF) and PTIP in different RMECs by WB (Fig. 6D–I). Compared with the model + si-NC group, the protein expressions of MMP9, MMP3, EGR3, and VEGF in the model + si-PTIP group were significantly increased (P < 0.05), while the protein expression of PTIP in the model + si-PTIP group was significantly decreased (P < 0.05). Interestingly, as shown in Fig. 7A–E, the expression of angiogenic-related proteins (MMP9, MMP3, EGR3, and VEGF) in RMECs of different groups was detected by immunofluorescence, and the results were consistent with that of WB. The above results indicate that interfering PTIP can promote angiogenesis of RMECs treated with high glucose.Figure 6.Effect of interfering PTIP on angiogenesis of RMECs treated with high glucose. (A) The tube formation ability of different RMECs was detected; (B**, **C) quantitative analysis of tube formation ability in different RMECs; (D) the protein expressions of MMP9, MMP3, EGR3, VEGF, and PTIP in different RMECs were detected by WB; (E–I) quantitative analysis of protein expression in different RMECs, (E) MMP9, (F) MMP3, (G) EGR3, (H) VEGF, and (I) PTIP. Data are presented as the mean ± SD. *P < 0.05 vs. control; ^#^P < 0.05 vs. model + si-NC.Figure 7.Effect of interfering PTIP on the protein expressions of VEGF, EGR3, MMP3, and MMP9 of RMECs treated with high glucose. (A) Immunofluorescence results of different RMECs. (B–E) Quantitative analysis of protein expression in different RMECs, (B) VEGF, (C) EGR3, (D) MMP3, and (E) MMP9.
Discussion
Diabetic retinopathy (DR) is the most prevalent microvascular complication of diabetes and a leading cause of visual impairment and blindness in diabetic patients (Chong et al. 2024; Dorweiler et al. 2024). Currently, there are limited clinical treatment options available for slowing the progression of DR. Therefore, it is imperative to elucidate the regulatory mechanisms underlying DR and develop novel therapeutic strategies to delay its progression. The early clinical manifestations of diabetic retinopathy are characterized by structural and functional impairments in retinal microvasculature, including disruption of endothelial cell tight junctions and compromised integrity of the blood-retinal barrier. A hyperglycemic milieu can directly induce damage to RMECs, resulting in altered cellular behaviors such as dysregulated proliferation, impaired migration, and defective lumen formation. These pathological alterations closely mirror the hallmark features observed in diabetic retinopathy, including vascular leakage and pathological neovascularization (Niu et al. 2025; Shi et al. 2025). In numerous studies, RMECs exposed to high glucose have been utilized as in vitro models of DR to investigate the effects of specific genes on the disease (Fu et al. 2023; Xue et al. 2023; Yu et al. 2023). In this study, an in vitro DR model was established by exposing RMECs to high-glucose conditions. It was observed that the expression level of PTIP in high-glucose-treated RMECs was significantly down-regulated, suggesting that PTIP plays a role in regulating the development of the in vitro DR model.
The abnormal proliferation, migration, and angiogenesis of RMECs are central pathological mechanisms in DR (Mai et al. 2023; Qin et al. 2023; Su et al. 2023). High-glucose stimulation induces abnormal proliferation and migration of endothelial cells (Wang et al. 2022). Upon stimulation, quiescent endothelial cells acquire a “pro-angiogenic phenotype,” leading to their proliferation and migration into the surrounding matrix for new blood vessel formation (Gu et al. 2021). Additionally, high-glucose exposure significantly enhances the tube formation capacity of RMECs, contributing to abnormal retinal neovascularization (Cao et al. 2021a, b; Wang et al. 2024). These newly formed vessels are fragile and prone to leakage, which can result in retinal edema, hemorrhage, vitreous hemorrhage, and tractional retinal detachment (Chen et al. 2025). Therefore, this study investigated the effects of PTIP on the proliferation, migration, and tube formation ability of RMECs under high-glucose conditions. The findings demonstrate that overexpression of PTIP markedly suppresses the proliferation, migration, and tube formation ability of high-glucose-treated RMECs. In contrast, PTIP knockdown significantly promotes these processes in RMECs exposed to high glucose.
In addition, inflammatory response and oxidative stress are critical factors contributing to vascular endothelial cell injury in DR (Zou et al. 2022; Padovani-Claudio et al. 2024). In a hyperglycemic environment, oxidative stress and inflammation are significantly elevated, leading to reduced SOD enzyme activity and increased levels of MDA, TNF-α, and IL-6 (Yu et al. 2015; Chen et al. 2024). These findings align with our research results. Furthermore, our study demonstrated that overexpression of PTIP could effectively suppress high glucose-induced oxidative stress (restoring SOD activity and reducing MDA levels) and inflammatory responses (decreasing TNF-α and IL-6 levels) in RMECs. Conversely, interfering with PTIP expression exacerbates the high-glucose-induced increase in oxidative stress and inflammatory markers in RMECs.
VEGF, a key vascular endothelial growth factor, drives the activation of endothelial cells (Alsoudi et al. 2024). MMP3 and MMP9 degrade and remodel extracellular matrix (ECM) components, creating space for endothelial cell migration and the formation of new blood vessels (Salzmann et al. 2000; Wei et al. 2021). EGR3, as a stress-responsive transcription factor, activates inflammatory genes, thereby indirectly promoting the inflammatory response of the vascular endothelium (Bai et al. 2024). The synergistic actions of these three factors can facilitate pathological neovascularization in DR. Our research demonstrates that overexpression of PTIP significantly suppresses the expression of VEGF, MMP3, MMP9, and EGR3 proteins in RMECs. Conversely, interfering PTIP markedly enhances the expression of these proteins in RMECs. In summary, overexpression of PTIP may inhibit the progression of DR by suppressing the proliferation, migration, tube formation, oxidative stress, and inflammatory responses in RMECs. However, this study also has some limitations. Additional animal and clinical investigations are necessary to obtain conclusive evidence regarding the regulatory impact of PTIP on DR. In addition, Han et al. demonstrated that PTIP suppresses the invasion of esophageal squamous cell carcinoma cells through modulation of EphA2 expression (Han et al. 2021). Nakata et al. demonstrated that PTIP epigenetically regulates DNA damage-induced cell cycle arrest by upregulating PRDM1 (Nakata et al. 2024). Currently, the specific signaling pathway in RMECs regulated by PTIP remains unclear. Future studies will aim to address these limitations through further investigation.
